Arvinas Inc (ARVN)

$7.42 -0.02 (-0.27%)
Market Cap 541.59M
Revenue (ttm) 263.40M
Net Income (ttm) -198.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -75.51%
Debt to Equity Ratio 0.00
Volume 1,465,800
Avg Vol 2,001,564
Day's Range N/A - N/A
Shares Out 72.99M
Stochastic %K 22%
Beta 2.22
Analysts Strong Sell
Price Target $19.36

Company Profile

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders f...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 535 1456
Address:
5 Science Park, 395 Winchester Avenue, New Haven, United States
buyandsold
buyandsold Aug. 2 at 6:58 AM
$ARVN i guess the chances they are selling up tp $PFE for $21 are low, but that is what I want so I can gamble all profts on Serepta
1 · Reply
Wisenheimer
Wisenheimer Jul. 31 at 3:01 PM
$ARVN may have delayed to position statement if they got rejected by fda on the nda
3 · Reply
Secret71
Secret71 Jul. 31 at 1:38 PM
$ARVN earnings now on the 6th? What is happening,maybe a buyout?
0 · Reply
outlawinvestor1
outlawinvestor1 Jul. 30 at 8:30 PM
$ARVN Earnings release on Aug 6. They also mention the dreaded ‘corporate update’. https://ir.arvinas.com/news-releases/news-release-details/arvinas-report-second-quarter-2025-financial-results-august-6
1 · Reply
Secret71
Secret71 Jul. 29 at 8:05 PM
$ARVN Upcoming Earnings: Q2 '25 Reports: Jul 31, Pre-Market
0 · Reply
Greatguns
Greatguns Jul. 29 at 5:46 PM
$ARVN Earnings Call Sentiment| Positive The earnings call reflected a generally positive sentiment with significant progress in clinical trials, especially for Vepdegestrant and ARV-102. However, the removal of planned phase 3 trials and workforce reductions indicate challenges and strategic realignments.
0 · Reply
Secret71
Secret71 Jul. 29 at 2:04 PM
$ARVN i thought earnings were today at pre
1 · Reply
Secret71
Secret71 Jul. 29 at 1:56 PM
$ARVN nothing yet?
0 · Reply
biopuzzle
biopuzzle Jul. 28 at 8:55 PM
$ARVN another attempt to shake out cheap shares?
0 · Reply
Secret71
Secret71 Jul. 28 at 7:36 PM
$ARVN lucky 7 ?
0 · Reply
Latest News on ARVN
Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 30, 2025, 4:05 PM EDT - 4 days ago

Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025

Arvinas Announces Retirement of Chief Executive Officer and Succession Plan

Jul 9, 2025, 7:00 AM EDT - 25 days ago

Arvinas Announces Retirement of Chief Executive Officer and Succession Plan

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress

Jun 13, 2025, 7:00 AM EDT - 7 weeks ago

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

Jun 6, 2025, 7:00 AM EDT - 2 months ago

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting

Jun 5, 2025, 8:28 AM EDT - 2 months ago

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting

Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression

May 31, 2025, 8:06 AM EDT - 2 months ago

Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression

PFE

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

May 31, 2025, 8:00 AM EDT - 2 months ago

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

Arvinas to Present at Jefferies Global Healthcare Conference

May 30, 2025, 7:00 AM EDT - 2 months ago

Arvinas to Present at Jefferies Global Healthcare Conference

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Shareholders to Inquire about Securities Investigation

May 16, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Shareholders to Connect

May 15, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Shareholders to Reach Out

May 14, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Shareholders to Learn More About the Investigation

May 13, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Shareholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Investors to Learn More About the Investigation

May 12, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Investors to Learn More About the Investigation

Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 11, 2025, 10:00 AM EDT - 3 months ago

Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Investors to Connect

May 9, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Stockholders to Inquire about Securities Investigation

May 8, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Investors to Inquire about Securities Investigation

May 7, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Investors to Reach Out

May 6, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Investors to Reach Out

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Stockholders to Reach Out

May 5, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Stockholders to Reach Out

Arvinas: Yet Another Biotech Trading Below Net Cash, But It's Only A Mild Bull Case

May 4, 2025, 4:17 PM EDT - 3 months ago

Arvinas: Yet Another Biotech Trading Below Net Cash, But It's Only A Mild Bull Case

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Stockholders to Connect

May 4, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Stockholders to Connect

Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 2, 2025, 5:00 PM EDT - 3 months ago

Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Arvinas, Inc. (ARVN) Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation

May 2, 2025, 8:15 AM EDT - 3 months ago

Arvinas, Inc. (ARVN) Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation

Arvinas, Inc. (ARVN) Q1 2025 Earnings Call Transcript

May 1, 2025, 9:40 PM EDT - 3 months ago

Arvinas, Inc. (ARVN) Q1 2025 Earnings Call Transcript

Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 1, 2025, 7:00 AM EDT - 3 months ago

Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update

Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

Apr 28, 2025, 7:00 AM EDT - 3 months ago

Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting

Apr 28, 2025, 6:45 AM EDT - 3 months ago

Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting

Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 23, 2025, 10:44 AM EDT - 3 months ago

Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting

Apr 21, 2025, 7:00 AM EDT - 3 months ago

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting

Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study

Apr 4, 2025, 3:38 PM EDT - 4 months ago

Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study

Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation

Apr 4, 2025, 7:00 AM EDT - 4 months ago

Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation

Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer's & Parkinson's Diseases

Mar 27, 2025, 7:00 AM EDT - 4 months ago

Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer's & Parkinson's Diseases

buyandsold
buyandsold Aug. 2 at 6:58 AM
$ARVN i guess the chances they are selling up tp $PFE for $21 are low, but that is what I want so I can gamble all profts on Serepta
1 · Reply
Wisenheimer
Wisenheimer Jul. 31 at 3:01 PM
$ARVN may have delayed to position statement if they got rejected by fda on the nda
3 · Reply
Secret71
Secret71 Jul. 31 at 1:38 PM
$ARVN earnings now on the 6th? What is happening,maybe a buyout?
0 · Reply
outlawinvestor1
outlawinvestor1 Jul. 30 at 8:30 PM
$ARVN Earnings release on Aug 6. They also mention the dreaded ‘corporate update’. https://ir.arvinas.com/news-releases/news-release-details/arvinas-report-second-quarter-2025-financial-results-august-6
1 · Reply
Secret71
Secret71 Jul. 29 at 8:05 PM
$ARVN Upcoming Earnings: Q2 '25 Reports: Jul 31, Pre-Market
0 · Reply
Greatguns
Greatguns Jul. 29 at 5:46 PM
$ARVN Earnings Call Sentiment| Positive The earnings call reflected a generally positive sentiment with significant progress in clinical trials, especially for Vepdegestrant and ARV-102. However, the removal of planned phase 3 trials and workforce reductions indicate challenges and strategic realignments.
0 · Reply
Secret71
Secret71 Jul. 29 at 2:04 PM
$ARVN i thought earnings were today at pre
1 · Reply
Secret71
Secret71 Jul. 29 at 1:56 PM
$ARVN nothing yet?
0 · Reply
biopuzzle
biopuzzle Jul. 28 at 8:55 PM
$ARVN another attempt to shake out cheap shares?
0 · Reply
Secret71
Secret71 Jul. 28 at 7:36 PM
$ARVN lucky 7 ?
0 · Reply
buyandsold
buyandsold Jul. 24 at 2:52 AM
$ARVN lame duck CEO, a Vepdeg partnership that cant be executed on the agreed terms as the market size does not justify co commercialization. We need a strategic review We need something Anything
1 · Reply
NewGuyHere94
NewGuyHere94 Jul. 23 at 6:15 PM
$ARVN has to break $8 again 🤞
0 · Reply
buyandsold
buyandsold Jul. 17 at 5:30 PM
$ARVN any purchase at volume pushes price hard
0 · Reply
benja75
benja75 Jul. 10 at 6:35 PM
$ARVN Moving to the board chair after a 35 year career is normal. Usually these guys like to shift on a high note, so could be good for next quarter call.
1 · Reply
buyandsold
buyandsold Jul. 10 at 6:08 PM
$ARVN sell Vepdeg, liquidate
1 · Reply
360sage
360sage Jul. 9 at 2:15 PM
$ARVN The CEO moves to the chairman position only after a replacement is appointed. No change until a new CEO is found.
0 · Reply
buyandsold
buyandsold Jul. 9 at 1:28 PM
$ARVN CEO is out. Activists are going to get this sold/liquidated. All but skeleton staff soon, and a sale process that will see Pfizer buy for a bargain price a few bucks above cash.
2 · Reply
AVXLfraudsters
AVXLfraudsters Jul. 7 at 5:14 AM
$ARVN this shit is ass
1 · Reply
Escapee
Escapee Jul. 4 at 1:58 PM
$ARVN DCA adding like it’s my job
0 · Reply
TraderMK
TraderMK Jul. 3 at 12:27 AM
$ARVN looks ready to pop.
2 · Reply
JarvisFlow
JarvisFlow Jun. 30 at 8:48 PM
Oppenheimer has adjusted their stance on Arvinas ( $ARVN ), setting the rating to Outperform with a target price of 80 → 70.
1 · Reply
JarvisFlow
JarvisFlow Jun. 30 at 8:41 PM
Oppenheimer updates rating for Arvinas ( $ARVN ) to Outperform, target set at 95.
0 · Reply